Technology area: Biotechnology & Pharmaceuticals
53 pending office actions • 24 clients • 52 examiners • 40 art units • 0 of 53 (0%) have an AI response strategy ready
WOLTER VAN DYKE DAVIS, PLLC has 52 pending office actions in Biotechnology & Pharmaceuticals and 3433 career applications. Its resolved allowance rate is 85.28%, with an average of 3.29 office actions per allowance.
The profile reflects ongoing prosecution in a technology area where disclosure support and claim breadth often require close coordination. The allowance rate summarizes resolved outcomes across the reported application base, while the office-action average indicates that allowed matters typically require multiple exchanges with the Office. Practitioners can use the figures to structure docket review and response planning, but should not treat the aggregate measures as a substitute for application-specific analysis.
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (4%) |
| §101 + other | 5 (9%) |
| §103 only | 6 (11%) |
| §102 only | 5 (9%) |
| §112 only | 7 (13%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 2 (4%) |
| Multi-statute (no §101) | 25 (47%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 2 | 67.7% | +43.0% |
| MILO, MICHAEL | 1 | 50.8% | +52.5% |
| COHEN, STEFANIE J | 1 | 75.5% | +2.5% |
| ZHONG, WAYNESHAOBIN | 1 | 72.3% | +21.4% |
| PAULS, JOHN A | 1 | 49.0% | +27.7% |
| BROWN, KYLE MARTZ | 1 | 8.8% | +3.1% |
| RUSHING, MARK S | 1 | 76.8% | +23.5% |
| TIWARI, VYOMA SHUBHAM | 1 | 32.1% | +47.4% |
| FARDANESH, MARJAN | 1 | 72.6% | +19.0% |
| WEHRHEIM, LINDSEY GAIL | 1 | 78.9% | +19.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18178192 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FETTEROLF, BRANDON J | 56d overdue |
| 18709666 | SYSTEMS AND METHODS TO IMPROVE PATIENT SELF-ADMINISTRATION | EGLOFF, PETER RICHARD | 35d overdue |
| 17370759 | IDENTIFYING TRANSITION POINTS IN CHEMICAL REACTIONS | MINCHELLA, KAITLYN L | 1d overdue |
| 17432177 | LIF THERAPY FOR INDUCING INTESTINAL EPITHELIAL CELL REGENERATION | XIE, XIAOZHEN | 12d |
| 18252069 | METHOD OF SENSITIZING CANCERS TO IMMUNOTHERAPY USING IMMUNOMODULATORY AGENTS | REYNOLDS, FRED H | 16d |
| 17774215 | METHODS FOR DISTINGUISHING THE STAGES OF BACTERIAL VAGINOSIS | MCKNIGHT, CIARA A | 19d |
| 18777102 | BAG-IN-BOX PACKAGING | DEMEREE, CHRISTOPHER R | 21d |
| 17614076 | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING AMPHIPHILIC ACTIVE INGREDIENTS | MERCIER, MELISSA S | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715258 | ENERGY HARVESTING SUBSTANCE EVENT MONITORING SYSTEM | RUSHING, MARK S | 26d |
| 19549567 | CHEST AND ABDOMEN RESTRICTION DEVICE | MILO, MICHAEL | — |
| 19220933 | METHODS AND COMPOSITIONS FOR PLANT PATHOGEN RESISTANCE IN PLANTS | ZHONG, WAYNESHAOBIN | — |
| 19174481 | MONITORING USAGE OF A HEMORRHOID TREATMENT DEVICE AT A SURGICAL CENTER | PAULS, JOHN A | — |
| 18870030 | CELL-FREE DNA CONCENTRATION IN HYPOTHERMIC MACHINE PERFUSATE AS A RAPID MARKER FOR KIDNEY GRAFT QUALITY | TIWARI, VYOMA SHUBHAM | — |
| 18869522 | TECHNIQUES FOR MEASURING ATYPICAL NEURODEVELOPMENT IN NEONATES BASED ON AUDITORY BRAINSTEM RESPONSE (ABR) TESTS | FARDANESH, MARJAN | — |
| 18865936 | APPARATUS AND METHOD FOR DETERMINING STIMULATION PARAMETERS FOR DEEP BRAIN STIMULATION (DBS) | WEHRHEIM, LINDSEY GAIL | — |
| 18236078 | PROTEIN-PEG INTERACTIONS THAT REDIRECT THE THERMAL UNFOLDING PATHWAY OF PEGYLATED HUMAN GALECTIN-3C | ROBINSON, HOPE A | — |
| Art Unit | Apps |
|---|---|
| 1662 | 3 |
| 1674 | 3 |
| 1613 | 3 |
| 3715 | 2 |
| 1658 | 2 |
| 1642 | 2 |
| 1656 | 2 |
| 1652 | 2 |
| 3786 | 1 |
| 3683 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19549567 | CHEST AND ABDOMEN RESTRICTION DEVICE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | MILO, MICHAEL | 3786 | §102§103 | Non-Final OA | — | Pending | Feb 25, 2026 |
| 19232930 | THICKNESS-LIMITED ELECTROSPRAY DEPOSITION | Rutgers, The State University Of New Jersey | COHEN, STEFANIE J | §102 | Non-Final OA | — | Pending | Jun 10, 2025 | |
| 19220933 | METHODS AND COMPOSITIONS FOR PLANT PATHOGEN RESISTANCE IN PLANTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | ZHONG, WAYNESHAOBIN | 1662 | §112 | Non-Final OA | — | Pending | May 28, 2025 |
| 19174481 | MONITORING USAGE OF A HEMORRHOID TREATMENT DEVICE AT A SURGICAL CENTER | Medfiniti Ip, LLC | PAULS, JOHN A | 3683 | §101§103 | Non-Final OA | — | Pending | Apr 09, 2025 |
| 19174497 | OPERATION OF A HEMORRHOID TREATMENT DEVICE AT A SURGICAL CENTER | Medfiniti Ip, LLC | BROWN, KYLE MARTZ | 3794 | §102§103 | Non-Final OA | — | Pending | Apr 09, 2025 |
| 18715258 | ENERGY HARVESTING SUBSTANCE EVENT MONITORING SYSTEM | Noble International, LLC | RUSHING, MARK S | 2689 | §103 | Final Rejection | 26d | Pending | Dec 19, 2024 |
| 18870030 | CELL-FREE DNA CONCENTRATION IN HYPOTHERMIC MACHINE PERFUSATE AS A RAPID MARKER FOR KIDNEY GRAFT QUALITY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | TIWARI, VYOMA SHUBHAM | 1634 | §103§112 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18869522 | TECHNIQUES FOR MEASURING ATYPICAL NEURODEVELOPMENT IN NEONATES BASED ON AUDITORY BRAINSTEM RESPONSE (ABR) TESTS | Rutgers, The State University Of New Jersey | FARDANESH, MARJAN | 3791 | §103 | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18865936 | APPARATUS AND METHOD FOR DETERMINING STIMULATION PARAMETERS FOR DEEP BRAIN STIMULATION (DBS) | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | WEHRHEIM, LINDSEY GAIL | 3799 | §102 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18862702 | AR MARKER FOR INJECTION | Noble International, LLC | HULL, JAMES B | 3715 | §102§103 | Non-Final OA | — | Pending | Nov 04, 2024 |
| 18857231 | SMALL MOLECULE INDUCERS OF CARDIOMYOCYTES TO IMPROVE CARDIAC STRUCTURE AND FUNCTION | UNIVERSITY OF MARYLAND, BALTIMORE | WHITE, DAWANNA SHAR-DAY | 1627 | §103§112 | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18904760 | UTILIZATION OF STATIC STRUCTURES IN ADVANCED BUILDING ENVELOPE SYSTEMS TO IMPROVE LIGHTING, THERMAL, ACOUSTIC, AND STORM PROTECTION PERFORMANCE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | CHOI, ALICIA M | §102§103§112 | Non-Final OA | — | Pending | Oct 02, 2024 | |
| 18845468 | ATTENUATED MATURATION-DEFECTIVE CHLAMYDIA VACCINES | Rutgers, The State University Of New Jersey | GRASER, JENNIFER E | 1645 | §102§103§112 | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18816363 | FIN ARRANGEMENT FOR CANTED TOWER SUPPORT | Roswell U.S. Llc. | VENNE, DANIEL V | 3615 | §112 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18790141 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | UNIVERSITY OF MARYLAND, BALTIMORE | RAO, SAVITHA M | 1691 | §103DP | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18777102 | BAG-IN-BOX PACKAGING | DMK DEUTSCHES MILCHKONTOR GMBH | DEMEREE, CHRISTOPHER R | 3734 | §103§112 | Non-Final OA | 21d | Pending | Jul 18, 2024 |
| 18761250 | DIAGNOSIS AND TREATMENT OF VASODILATORY SHOCK | UNIVERSITY OF MARYLAND, BALTIMORE | VARADARAJ, ARCHANA | 1658 | §101§102 | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18720914 | APPARATUS AND METHOD TO PROVIDE A PATHOGENICIDAL BARRIER BETWEEN FIRST AND SECOND REGIONS | X Cell, LLC | THROWER, LARRY W | 1754 | §102§103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18576480 | ANIONIC EXPLOSION-PROOF MEMBRANE AND PREPARATION METHOD THEREFOR | Hubei Institute Of Aerospace Chemical Technology | DESAI, ANISH P | 1788 | §112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18711193 | FRAGRANCES AND FRAGRANCE MIXTURES | Symrise AG | AHVAZI, BIJAN | 1763 | §103§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18665956 | METHOD FOR MANUFACTURING SEMI-HARD CHEESE | DMK DEUTSCHES MILCHKONTOR GMBH | TRAN, LIEN THUY | 1793 | §103§112 | Final Rejection | — | Pending | May 16, 2024 |
| 18709666 | SYSTEMS AND METHODS TO IMPROVE PATIENT SELF-ADMINISTRATION | Noble International, LLC | EGLOFF, PETER RICHARD | 3715 | §101 | Non-Final OA | 35d overdue | Pending | May 13, 2024 |
| 18706881 | IMPROVED GENETIC TRANSFORMATION BY IMPROVING DE-NOVO SHOOT REGENERATION IN ADULT PLANTS AND DURING IN-VITRO TISSUE CULTURE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | JOHNSON, EMILY KATHARINE | 1662 | §102§103§112 | Final Rejection | — | Pending | May 02, 2024 |
| 18704191 | OPTIMIZING IMMUNOSUPPRESSION IN TRANSPLANT PATIENTS USING PERSONALIZED PHENOTYPIC DOSING MODEL | The Regents of the University of California | XIAO, YAN | 1642 | §102Other | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18686633 | RADIATION COMPATIBLE EXPANDER FOR BREAST RECONSTRUCTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | FLORES, ADRIAN | 3774 | §102§103 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18409738 | SIMPLIFIED QUANTITATIVE ANALYSIS USING SUBSTRATES WITH PRE-LOADED STANDARDS | Capitainer AB | HYUN, PAUL SANG HWA | 1796 | §103§112 | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18539597 | PREBIOTIC FORMULATIONS | DMK DEUTSCHES MILCHKONTOR GMBH | LI, CHANGQING | 1791 | §102§103 | Final Rejection | 26d | Pending | Dec 14, 2023 |
| 18279672 | NOVEL PSEUDOMONAS STRAIN FOR METAL RECOVERY | Brain Biotech AG | STEADMAN, DAVID J | 1656 | §101 | Final Rejection | — | Pending | Aug 31, 2023 |
| 18236078 | PROTEIN-PEG INTERACTIONS THAT REDIRECT THE THERMAL UNFOLDING PATHWAY OF PEGYLATED HUMAN GALECTIN-3C | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18038321 | USE OF INSULIN-LIKE GROWTH FACTORS WITH GAMMA-CHAIN CYTOKINES TO INDUCE HOMEOSTATIC PROLIFERATION OF LYMPHOCYTES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | SULLIVAN, DENNIS JOHN | 1642 | §103 | Non-Final OA | — | Pending | May 23, 2023 |
| 18321062 | COMPOSITION AND METHOD FOR CONTROLLING HEAT GENERATION WITHIN ORGANISM, AND USE | Guangdong Jiantebo Biotechnology Co., Ltd. | HOWARD, ZACHARY C | 1674 | §112 | Final Rejection | — | Pending | May 22, 2023 |
| 18037364 | MULTIFUNCTION MICROFLUIDIC OPTRODE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | ROANE, AARON F | 3796 | §102 | Non-Final OA | — | Pending | May 17, 2023 |
| 18252069 | METHOD OF SENSITIZING CANCERS TO IMMUNOTHERAPY USING IMMUNOMODULATORY AGENTS | The Regents of the University of California | REYNOLDS, FRED H | 1658 | §102§103§112 | Final Rejection | 16d | Pending | May 08, 2023 |
| 18137022 | METHODS AND COMPOSITIONS FOR CONTROL OF ARTHROPOD PESTS | Greenlight Biosciences, Inc. | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | — | Pending | Apr 20, 2023 |
| 18028937 | CANNABIS PLANT DERIVED EXTRACELLULAR VESICLES AND THERAPEUTIC METHODS USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | LEE, SIN J | 1613 | §103§112 | Final Rejection | — | Pending | Mar 28, 2023 |
| 18125949 | TREATMENT OF AQUEOUS SYSTEMS | Mfg Chemical, LLC | GEISBERT, WILLIAM ADDISON | 1779 | §103§112 | Non-Final OA | — | Pending | Mar 24, 2023 |
| 18178192 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | The Trustees of Columbia University in the City of New York | FETTEROLF, BRANDON J | 1626 | §102§103§112 | Non-Final OA | 56d overdue | Pending | Mar 03, 2023 |
| 18015160 | COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY | Symrise AG | BROWE, DAVID | 1617 | §102§112 | Non-Final OA | — | Pending | Jan 09, 2023 |
| 18015169 | BIOFLUID-BASED PROTEIN AND MIRNA BIOMARKERS FOR NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY | The United States Department of Veterans Affairs | MCCOLLUM, ANDREA K | 1674 | §101§102§112 | Non-Final OA | 60d | Pending | Jan 09, 2023 |
| 17911789 | METHODS OF TREATING VIRAL INFECTIONS AND HEALTH CONSEQUENCES | Allen Davidoff | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | — | Pending | Sep 15, 2022 |
| 17818159 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | Xortx Therapeutics, Inc. | HUANG, GIGI GEORGIANA | 1613 | §103§112DP | Final Rejection | 14d | Pending | Aug 08, 2022 |
| 17797217 | CIRCULAR BIFUNCTIONAL APTAMERS AND TRIFUNCTIONAL APTAMERS TARGETING Tau | The United States Department of Veterans Affairs | YU, DAVID TUYANG | 1635 | §103§112 | Non-Final OA | — | Pending | Aug 03, 2022 |
| 17614076 | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING AMPHIPHILIC ACTIVE INGREDIENTS | Pharmadev SA | MERCIER, MELISSA S | 1615 | §102§103 | Final Rejection | 21d | Pending | Jul 11, 2022 |
| 17774215 | METHODS FOR DISTINGUISHING THE STAGES OF BACTERIAL VAGINOSIS | UNIVERSITY OF MARYLAND, BALTIMORE | MCKNIGHT, CIARA A | 1656 | §101§103 | Non-Final OA | 19d | Pending | May 04, 2022 |
| 17615894 | A COOLING PREPARATION | Symrise AG | BERRIOS, JENNIFER A | 1613 | §103 | Final Rejection | — | Pending | Dec 02, 2021 |
| 17490268 | METHOD FOR OPERATING HEALTH-CARE DEVICE | Tao Mining Co., Ltd. | NEMER, OSAMA MOHAMMAD | 3771 | §103 | Final Rejection | 4d overdue | Pending | Sep 30, 2021 |
| 17598695 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | The Trustees Of Columbia Universityin The City Of New York | ROMERO, KRISTEN WANG | 1624 | §102Other | Non-Final OA | 73d overdue | Pending | Sep 27, 2021 |
| 17478015 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECT PESTS | Greenlight Biosciences, Inc. | ZHENG, LI | 1662 | §112 | Non-Final OA | 70d overdue | Pending | Sep 17, 2021 |
| 17432177 | LIF THERAPY FOR INDUCING INTESTINAL EPITHELIAL CELL REGENERATION | Rutgers, The State University Of New Jersey | XIE, XIAOZHEN | 1674 | §103§112 | Final Rejection | 12d | Pending | Aug 19, 2021 |
| 17370759 | IDENTIFYING TRANSITION POINTS IN CHEMICAL REACTIONS | Azure Vault Ltd. | MINCHELLA, KAITLYN L | 1685 | §101§112Other | Non-Final OA | 1d overdue | Pending | Jul 08, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial85.3% of resolved applications prosecuted by Wolter Van Dyke Davis, Pllc were allowed, across 3,433 applications in USPTO records.
3.29 office actions per allowed application on average.
53 pending office actions as of October 2026, for 24 clients, before 52 examiners in 40 art units.
